These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1263 related items for PubMed ID: 23897961

  • 1. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P.
    J Clin Oncol; 2013 Sep 10; 31(26):3279-87. PubMed ID: 23897961
    [Abstract] [Full Text] [Related]

  • 2. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
    Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM.
    J Clin Oncol; 2012 Aug 20; 30(24):2946-55. PubMed ID: 22802322
    [Abstract] [Full Text] [Related]

  • 3. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G.
    J Clin Oncol; 2012 Jul 10; 30(20):2475-82. PubMed ID: 22585692
    [Abstract] [Full Text] [Related]

  • 4. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.
    Jpn J Clin Oncol; 2009 Jul 10; 39(7):449-55. PubMed ID: 19487425
    [Abstract] [Full Text] [Related]

  • 5. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.
    Cancer; 2010 Jul 01; 116(13):3143-51. PubMed ID: 20564642
    [Abstract] [Full Text] [Related]

  • 6. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.
    Ann Hematol; 2012 Feb 01; 91(2):249-56. PubMed ID: 21789621
    [Abstract] [Full Text] [Related]

  • 7. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M, GIMEMA Italian Myeloma Network.
    Lancet; 2010 Dec 18; 376(9758):2075-85. PubMed ID: 21146205
    [Abstract] [Full Text] [Related]

  • 8. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.
    J Clin Oncol; 2010 Feb 10; 28(5):800-7. PubMed ID: 20048187
    [Abstract] [Full Text] [Related]

  • 9. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
    Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL.
    J Clin Oncol; 2013 Jan 10; 31(2):247-55. PubMed ID: 23091109
    [Abstract] [Full Text] [Related]

  • 10. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
    Huang H, Zhou L, Peng L, Fu W, Zhang C, Hou J.
    Leuk Res; 2014 Sep 10; 38(9):1048-54. PubMed ID: 25052306
    [Abstract] [Full Text] [Related]

  • 11. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
    Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH, Korean Multiple Myeloma Working Party.
    Ann Hematol; 2010 Sep 10; 89(9):905-12. PubMed ID: 20349060
    [Abstract] [Full Text] [Related]

  • 12. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
    Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH, Mazumder A, Crowley J, Becker P, Hilger J, Durie BG.
    Br J Haematol; 2010 Feb 10; 148(4):562-8. PubMed ID: 19919652
    [Abstract] [Full Text] [Related]

  • 13. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
    Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P.
    J Clin Oncol; 2010 Oct 20; 28(30):4621-9. PubMed ID: 20823406
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C, Ruehle K, Westphal S, Meisenberg B.
    Clin Lymphoma Myeloma; 2006 Nov 20; 7(3):210-6. PubMed ID: 17229337
    [Abstract] [Full Text] [Related]

  • 15. Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
    Nooka AK, Kaufman JL, Behera M, Langston A, Waller EK, Flowers CR, Gleason C, Boise LH, Lonial S.
    Cancer; 2013 Dec 01; 119(23):4119-28. PubMed ID: 24005889
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
    Li J, Liu JR, Huang BH, Chen M, Zheng D, Xu DR, Zou WY.
    Zhonghua Nei Ke Za Zhi; 2012 Apr 01; 51(4):279-83. PubMed ID: 22781947
    [Abstract] [Full Text] [Related]

  • 18. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A, Duan Q, Liu X, Ding K, Han Y, Zhu W, Cai X, Wu J, Sun Z.
    Ann Hematol; 2012 Nov 01; 91(11):1779-84. PubMed ID: 22773209
    [Abstract] [Full Text] [Related]

  • 19. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
    Leiba M, Kedmi M, Duek A, Freidman T, Weiss M, Leiba R, Nagler A, Avigdor A.
    Br J Haematol; 2014 Sep 01; 166(5):702-10. PubMed ID: 24861981
    [Abstract] [Full Text] [Related]

  • 20. Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.
    Chim CS, Lie AK, Chan EY, Liu HS, Lau CW, Yip SF, Sim J, Wan TS, Ma ES, Liang R, Tse E, Kwong YL, Hong Kong Society of Myeloma.
    J Hematol Oncol; 2012 Jun 08; 5():28. PubMed ID: 22682027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.